Access to CBD products in New Zealand is relatively straightforward, with patients able to seek a prescription for CBD products just as they can for any other prescription medicine without the need for government approvals on a case-by-case basis as was previously required.
As a result, New Zealand has, proportionally, a far larger immediately accessible patient population compared to Australia given the regulatory hurdles for supply of medicinal cannabis to patients in Australia.
In order to provide prescribers with the best available information on CBD products to assist in making decisions on prescribing them to patients, THC provided financial assistance to DATAPHARM, a healthcare company in New Zealand, to launch CBDinfo.co.nz.
CBDinfo is a platform providing medical practitioners relevant and evidenced information about the use, availability, and potential benefits and risks of using CBD products.
Since launch in June 2019, over 100 medical practitioners have enrolled.
Once enrolled, practitioners can access detailed information on efficacy and safety data, as well as details on how to prescribe CBD products.
Initial sales have been positive
THC’s import and distribution process makes Endoca products available to all wholesalers in New Zealand, rather than a specialised subset or specific region.
Initial sales levels have been positive, supporting THC’s focus on doctor education and information provision as a means of responsibly supporting medical professionals and patients in the use of CBD.
The supply pathways and prescriber engagement and education activities THC has developed with the distribution of the Endoca product range will allow for THC to enter the New Zealand market with its own Australian produced medicine range next year.
THC’s medicine range for export next year will be pharmaceutical Good Manufacturing Practice (GMP) certified medicines produced from its Southport Manufacturing Facility.